Biotechnology

New tentative approval for Sandoz Inc drug rifaximin

Written by DrugPatentWatch – Make Better Decisions Posted on March 25, 2024 Less than 0 min read

Rifaximin is the generic ingredient in a single branded drug marketed by Salix Pharms and is included in a single NDA. There are twenty-nine patents defending this compound.

Drug patent litigation for RIFAXIMIN.

This ingredient has 100 and eigthy-two patent members of the family in thirty-nine nations.

Three suppliers are listed for this compound. There are two tentative approvals for this compound.

For extra info on how DrugPatentWatch might help together with your pharmaceutical enterprise intelligence wants, contact admin@DrugPatentWatch.com or go to www.DrugPatentWatch.com